三诺生物
(300298)
| 流通市值：78.26亿 | | | 总市值：97.15亿 |
| 流通股本：4.51亿 | | | 总股本：5.60亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,453,271,477.26 | 2,263,667,609.81 | 1,041,603,772.08 | 4,443,123,570.61 |
| 营业收入 | 3,453,271,477.26 | 2,263,667,609.81 | 1,041,603,772.08 | 4,443,123,570.61 |
| 二、营业总成本 | 3,338,133,962.97 | 2,116,582,036 | 988,932,886.51 | 4,041,229,082.16 |
| 营业成本 | 1,764,409,923.1 | 1,089,757,549.22 | 534,417,807.82 | 2,004,722,409.58 |
| 税金及附加 | 33,673,942.46 | 22,514,843.29 | 9,951,649.7 | 44,132,130.82 |
| 销售费用 | 926,492,495.02 | 611,075,641.74 | 289,301,393.26 | 1,191,774,591.77 |
| 管理费用 | 354,668,196.17 | 217,307,518.54 | 76,253,398.4 | 405,530,062.59 |
| 研发费用 | 224,193,796.26 | 145,011,761.61 | 73,478,693.59 | 374,997,672.43 |
| 财务费用 | 34,695,609.96 | 30,914,721.6 | 5,529,943.74 | 20,072,214.97 |
| 其中:利息费用 | 29,333,003.23 | 18,691,033.72 | 9,931,869.94 | 47,465,477.96 |
| 其中:利息收入 | 17,483,947.84 | 11,214,148.31 | 5,367,908.32 | -20,506,208.52 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 558,193.25 | - | - | - |
| 加:投资收益 | 1,308,350.85 | 825,810.72 | -130,675.78 | -1,595,366.95 |
| 资产处置收益 | -603,543.7 | -325,746.84 | -10,984.28 | 957,336.24 |
| 资产减值损失(新) | -1,112,227.84 | 2,659,106.97 | -2,953,281.89 | -74,396,452.82 |
| 信用减值损失(新) | 10,955,465.21 | 1,200,479.5 | 8,105,146.32 | -28,390,059.42 |
| 其他收益 | 50,372,354.23 | 40,968,719.21 | 35,405,935.83 | 100,507,784.2 |
| 四、营业利润 | 176,616,106.29 | 192,413,943.37 | 93,087,025.77 | 398,977,729.7 |
| 加:营业外收入 | 14,892,090.65 | 14,847,306.54 | 52,016.35 | 644,980.99 |
| 减:营业外支出 | 740,973.1 | 385,463.41 | 91,045.09 | 4,361,528.28 |
| 五、利润总额 | 190,767,223.84 | 206,875,786.5 | 93,047,997.03 | 395,261,182.41 |
| 减:所得税费用 | 38,023,274.68 | 24,804,658.66 | 11,686,920.17 | 49,406,583.44 |
| 六、净利润 | 152,743,949.16 | 182,071,127.84 | 81,361,076.86 | 345,854,598.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 152,743,949.16 | 182,071,127.84 | 81,361,076.86 | 345,854,598.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 211,003,372.35 | 180,654,708.01 | 72,115,093.5 | 326,290,993.05 |
| 少数股东损益 | -58,259,423.19 | 1,416,419.83 | 9,245,983.36 | 19,563,605.92 |
| 扣除非经常损益后的净利润 | 180,384,969.71 | 158,279,651.88 | 66,841,779.15 | 294,640,718.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.38 | 0.33 | 0.13 | 0.59 |
| (二)稀释每股收益 | 0.38 | 0.33 | 0.13 | 0.59 |
| 八、其他综合收益 | -4,351,539.6 | 13,304,077.19 | -7,243,403.27 | 24,447,503.61 |
| 归属于母公司股东的其他综合收益 | -5,958,810.65 | 4,913,796.74 | -5,524,488.46 | 24,206,678.54 |
| 九、综合收益总额 | 148,392,409.56 | 195,375,205.03 | 74,117,673.59 | 370,302,102.58 |
| 归属于母公司股东的综合收益总额 | 205,044,561.7 | 185,568,504.75 | 66,590,605.04 | 350,497,671.59 |
| 归属于少数股东的综合收益总额 | -56,652,152.14 | 9,806,700.28 | 7,527,068.55 | 19,804,430.99 |
| 公告日期 | 2025-10-24 | 2025-08-28 | 2025-04-29 | 2025-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |